Every Day is a New Day

News / Company News

Company News

Leto Laboratories Announces Appointment of CMO, Advancing the Development of Its Clinical Pipeline

Published: July 1, 2021


News summary
Leto Laboratories today announced the appointment of Chief Medical Officer: Dr. XIE Heng, a renowned expert in clinical research on anticancer drugs, and he officially joins the company in July 2021. Leto Laboratories is an innovation and R&D- driven platform company for biotechnology. It focuses on the engineering and process design for recombinant proteins, developing drugs of this kind covering polypeptides, cytokines and enzymes, and has made industry- leading achievements.

Prior to Leto, Dr. Xie served as Chief Medical Officer in Shenzhen Salubris Pharmaceuticals Co., Ltd., where he was responsible for the R&D evaluation and clinical strategy of innovative medicines. He’s also the Executive Editor of Journal of the National Cancer Center China (JNCC) and an advisor to the National Cancer Center.


Dr. Xie has been staying and working in the US for over 30 years. He has a PhD in Molecular and Cellular Pathology from the University of Alabama at Birmingham, holds an MPH degree from Johns Hopkins University, and owns the medical license to practice medicine in the US. He worked as Senior Medical Officer, Supervisory Medical Officer in National Institute of Health (NIH), the clinical medicine department of National Center for Advancing Translational Sciences (NCATS), Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI), and department for cancer treatment and clinical research in NCI. He is the only member with Chinese origin in DSMB/ DMC of SWOG and ECOG-ACRIN (cancer research networks under NCI), and the former Chair of Cancer Prevention and Control Clinical Trials Grant Program for the evaluation of protocols. Therefore, he is very experienced in the evaluation and oversight of cancer programs, and in translational medicine and clinical research. He has led a professional team consisting of physicians and doctoral students for translational clinical research and phase I to III clinical trials, where he was responsible for the evaluation, funding and supervision, which underpinned his extraordinary management experience.


Dr. ZHANG Wei, the Founder, Chairman and CEO of Leto Laboratories, said, “Dr. Xie’s joining us is a milestone for the development of Leto. This will speed up our clinical explorations worldwide, and will advance the clinical trials of a number of our innovative drugs and their commercialization process.”


Dr. XIE Heng said, “I’m honored to join Leto Laboratories, a company that is growing and with global visions. It possesses innovation-driven development concepts, forward-thinking strategic arrangement and unique and novel pipeline, and focuses on the unmet clinical needs. I believe we sure will fill in the treatment gaps by leveraging the resources we have in the home and abroad; we will make a difference through innovation!”


About Leto Laboratories

Leto Laboratories, founded in 2014, is a platform company for biotechnology driven by innovation and R&D, focusing on engineering and process design of recombinant proteins, and the drug development of this kind covering polypeptides, cytokines and enzymes. It uses its core technology- directional protein refolding and protein engineering to solve problems central to manufacturing and patent barriers problems in biopharmaceuticals and protein products development. Relying on these key technologies, Leto Laboratories aims to break up other countries’ monopoly in protein drug engineering and manufacturing, and bridge the technological gaps China faces in domestic industry.


Leto Laboratories has received fundings from SHERPA Healthcare Partners, Med-Fine Capital, Qirong Venture Capital, Hygeia Capital and other investors. In 2020, it closed Series B financing from Yijing Capital, Qiaojing Capital and Changping Development. In July 2021, the B+ round of financing from China Capital Management was completed. In the same year, it got strategic investment from TopAlliance.